5-Slide Series
Key findings from this edition, which tabulates monthly cases and deaths by state, are summarized below:
– We expect that more COVID deaths will occur in December than in any prior month in the US overall and in 33 states. December’s new COVID cases are at record highs nationally and in 35 states.
– The 3,400 new COVID deaths reported on December 16, are nearly 200 above the next-highest day the US has experienced to date.
– One positive development is that the percentage of monthly new cases resulting in death is far lower in more recent months (approximately 1%) than was the case during April and May (approximately 6%).
– Multiple points of research, including data we present herein, compellingly demonstrate that overall deaths in the USA during 2020 are far higher than occurred during 2019.
5-Slide Series
This edition of our 5 Slide Series is our 20th special edition focusing on the COVID-19 pandemic. As with all prior editions, we have tabulated several highly current data points. The newest type of analysis involves quantifying differences in COVID death rates per capita by race, showing that through June 7, African Americans have experienced more than twice the COVID-19 per capita death rate as Whites, Latinos, and Asians. We also provide various statistics regarding new confirmed cases and tests, nationally and state-by-state – including state rankings on the degree to which new confirmed cases have emerged in the past week.
5-Slide Series
This edition conveys our tabulations on the recent week’s COVID developments. A key finding is that while new cases decreased by 3% nationwide this past week relative to the prior week, more than half the nation’s population resides in a county where the number of new confirmed cases increased. A more encouraging finding is that while nearly 10,000 new COVID deaths occurred this past week, this figure was 5,246 lower than the previous week’s new death count.
We have also provided testing data for each state. Nationwide, less than 4% of the population has been tested as of May 20; state-level figures range from a high of 11.4% in Rhode Island to a low of 2.2% in Idaho.
Publication
PCMA engaged The Menges Group to estimate the financial and programmatic value of managing the prescription drug benefit in the Medicaid managed care setting, comparing states that utilize MCOs – who contract with PBMs – for their prescription drug benefits to states that manage their prescription drug benefits in FFS. Using Medicaid prescription drug data reported by each state to the Centers for Medicare and Medicaid Services (CMS) for all Medicaid-paid pharmacy-dispensed prescriptions, we analyzed how prescription drug costs and usage vary depending on how prevalent managed care is in each state Medicaid program. We also analyzed the drug costs and usage within specific therapeutic drug classes.
5-Slide Series
This edition of the 5-slide series conveys four data tabulations: 1) distribution of COVID deaths by age; 2) distribution of COVID deaths by gender within each age cohort; 3) county level tabulations on new case growth; and 4) a set of state level statistics on confirmed cases and deaths.
5-Slide Series
This edition of the Series focuses on US counties, showing the degree to which Americans reside in counties that may have moved past their peak in terms of new cases (52.2%), versus residing in counties where confirmed cases per day are still trending upward (42.5%). This edition also conveys detailed data about the nation’s 25 counties with the largest per capita rate of confirmed COVID cases as of April 22, and about the nation’s 25 largest counties.
5-Slide Series
The September edition presents Medicaid data from our Pharmacy Practice, quantifying the differences in cost per prescription between the MCO and FFS settings in two selected high-volume therapeutic classes. In both drug classes (as occurs with Medicaid prescriptions overall), the MCO setting is achieving large percentage savings relative to FFS. However, the path taken to achieve these savings is quite different between the two drug classes shown.
5-Slide Series
Our July 2018 edition conveys summary data regarding the Medicaid MCO industry’s overall financial performance during CY2016 and CY2017.
